ArticleThe journal of allergy and clinical immunology. Global2025
Validation of the novel Eosinophilic Esophagitis Symptom Questionnaire.
Article in The journal of allergy and clinical immunology. Global, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03633617 (A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)
Who cites it
2 citing papers in PubMed.
- Eosinophilic gastrointestinal diseases.Nature reviews. Disease primers · 2026Review
- Baseline characteristics, treatment patterns, and long-term outcomes in patients with eosinophilic esophagitis initiating dupilumab in routine clinical practice: study protocol of a phase IV, prospective, observational, multicenter registry (EDESIA).Therapeutic advances in gastroenterology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The novel Eosinophilic Esophagitis Symptom Questionnaire (EoE-SQ) is a patient-reported outcome measure that assesses symptoms beyond dysphagia in adults and adolescents with eosinophilic esophagitis (EoE). Methods: The EoE-SQ was administered in the phase 3 R668-EE-1774 trial (NCT03633617), which assessed the efficacy and safety of dupilumab in adults and adolescents with EoE. Baseline and follow-up data were used to estimate its psychometric properties and to determine meaningful score change. Results: The sample included 239 patients (median [range] age, 24 [12-68] years). The EoE-SQ frequency/severity scores showed internal consistency and test-retest reliability. Construct validity was demonstrated through moderate-to-strong correlations between EoE-SQ frequency/severity and other EoE-specific patient-reported outcome measures at baseline (frequency, Conclusions: The EoE-SQ showed good reliability, construct validity, and responsiveness for the assessment of EoE symptoms beyond dysphagia and can be used in combination with existing patient-reported outcome questionnaires to evaluate the full breadth of symptoms experienced by adult and adolescent patients with EoE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.